A new two-year research collaboration in the UK will attempt to develop digital tools that could be used alongside approved therapies for people with dementia.
The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c
At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea, just ahead of an FDA advisory committee meeting that has raised confidence that the
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.